To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.
The purpose of the study is to evaluate the pharmacokinetics and safety of parsaclisib in participants With normal renal function and participants with renal impairment.
Advanced Malignancies
DRUG: parsaclisib
Pharmacokinetics Parameter Groups1-4 : Cmax of parsaclisib, Maximum Observed Plasma Concentration of parsaclisib, 4 Days|Pharmacokinetics Parameter Groups 1-4 : AUC 0-∞ of parsaclisib, Area Under the Concentration-time Curve From 0 to Infinity of parsaclisib, 4 Days|Pharmacokinetics Parameter Groups 1-4 : AUC(0-t) of parsaclisib, Area Under the concentration- time curve up to the last measurable concentration of parsaclisib, 4 Days|Pharmacokinetics Parameter Group 5: Cmax of parsaclisib, Maximum Observed Plasma Concentration of parsaclisib, 4 Days for period 1 and 2|Pharmacokinetics Parameter Group 5 : AUC 0-∞ of parsaclisib, Area Under the Concentration-time Curve From 0 to Infinity of parsaclisib, 4 Days for period 1 and 2|Pharmacokinetics Parameter Group 5: AUC(0-t) of parsaclisib, Area Under the concentration- time curve up to the last measurable concentration of parsaclisib, 4 Days for period 1 and 2
Number of Treatment Emergent Adverse Events (TEAE) Groups 1-4, Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment., up to 11 Days|Pharmacokinetics Parameter Groups 1-4 : tmax of parsaclisib, Time to reach maximum plasma concentration of parsaclisib, 4 Days|Pharmacokinetics Parameter Groups 1-4 : t1/2 of parsaclisib, Apparent terminal phase disposition half-life of parsaclisib, 4 Days|Pharmacokinetics Parameter Groups 1-4 : CL/F of parsaclisib, Oral dose clearance of parsaclisib, 4 Days|Pharmacokinetics Parameter Groups 1-4 : Vz/F of parsaclisib, Apparent oral dose volume of distribution of parsaclisib, 4 Days|Pharmacokinetics Parameter Group 5 : tmax of parsaclisib, Time to reach maximum plasma concentration of parsaclisib, 4 Days for period 1 and 2|Pharmacokinetics Parameter Group 5 : t1/2 of parsaclisib, Apparent terminal phase disposition half-life of parsaclisib, 4 Days for period 1 and 2|Pharmacokinetics Parameter Group 5 : CL/F of parsaclisib, Oral dose clearance of parsaclisib, 4 Days for period 1 and 2|Pharmacokinetics Parameter Group 5 : Vz/F of parsaclisib, Apparent oral dose volume of distribution of parsaclisib, 4 Days for period 1 and 2|Pharmacokinetics Parameter Group 5 during Dialysis - : AUC1-5 of parsaclisib, Area Under the Concentration-time Curve From 1 to 5 hrs. of parsaclisib, 4 Days for period 1 and 2|Number of Treatment Emergent Adverse Events (TEAE) Group 5, Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment., up to 18 Days
The purpose of the study is to evaluate the pharmacokinetics and safety of parsaclisib in participants With normal renal function and participants with renal impairment.